MENU
+Compare
GMAB
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$20.80
Change
-$0.42 (-1.98%)
Capitalization
13.38B

GMAB Genmab A/S ADS Forecast, Technical & Fundamental Analysis

an international biotechnology company, which develops human antibody therapeutics for the treatment of cancer and other diseases.

Industry Biotechnology
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for GMAB with price predictions
Jan 08, 2025

GMAB's Stochastic Oscillator is staying in overbought zone for 6 days

The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

GMAB broke above its upper Bollinger Band on January 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 27, 2024. You may want to consider a long position or call options on GMAB as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GMAB just turned positive on December 26, 2024. Looking at past instances where GMAB's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

GMAB moved above its 50-day moving average on January 06, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GMAB advanced for three days, in of 332 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.998) is normal, around the industry mean (14.746). P/E Ratio (20.825) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.754) is also within normal values, averaging (1.853). GMAB has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (4.943) is also within normal values, averaging (264.084).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
GMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

GMAB is expected to report earnings to rise 23.54% to 35 cents per share on February 12

Genmab A/S ADS GMAB Stock Earnings Reports
Q4'24
Est.
$0.35
Q3'24
Missed
by $0.02
Q2'24
Beat
by $0.01
Q1'24
Est.
$0.29
Q4'23
Missed
by $0.17
The last earnings report on November 06 showed earnings per share of 28 cents, missing the estimate of 30 cents. With 1.12M shares outstanding, the current market capitalization sits at 13.38B.
A.I. Advisor
published General Information

General Information

an international biotechnology company, which develops human antibody therapeutics for the treatment of cancer and other diseases.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
Carl Jacobsens Vej 30
Phone
+45 70202728
Employees
2204
Web
https://www.genmab.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
ACM.X1.5294680.064599
+4.41%
AC Milan Fan Token cryptocurrency
ORDI.X27.3134461.018003
+3.87%
ORDI cryptocurrency
POWR.X0.2883710.009142
+3.27%
Powerledger cryptocurrency
MBL.X0.0036350.000089
+2.51%
MovieBloc cryptocurrency
XLM.X0.4884370.006129
+1.27%
Stellar cryptocurrency

GMAB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GMAB has been loosely correlated with GNMSF. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if GMAB jumps, then GNMSF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMAB
1D Price
Change %
GMAB100%
-1.98%
GNMSF - GMAB
58%
Loosely correlated
-1.04%
AXON - GMAB
47%
Loosely correlated
+1.37%
CVAC - GMAB
39%
Loosely correlated
-1.91%
PGEN - GMAB
36%
Loosely correlated
N/A
VCYT - GMAB
35%
Loosely correlated
-1.27%
More